RESEARCH COMMUNICATION Anti-HER-2×anti-CD3 Bi-specific Antibodies Inhibit Growth of HCT-116 Colorectal Carcinoma Cells in Vitro and in Vivo

Colorectal carcinoma (CRC) is one of the most common malignancies in the world and the second most frequent cause of cancer-related death in the United States (Jemal et al., 2009). At present, traditional and combined therapeutic approaches (surgery, chemotherapy and radiation) for curing colorectal carcinoma does not show encouraging outcome. The five-year survival in the patients with stage III or IV disease is from 25 to 65 percent and from 5 to 7 percent, respectively. Recent years, antitumor T-cells and anti-tumor antigenic immunotherapy has become hot topics. Specifically, the role of protooncogene HER-2/neu in the diagnosis of cancers and the immunotherapy is progressing rapidly (Argyriou and Kalofonos 2009, Liu et al., 2012). It has been verified that Anti-HER-2 antibody has significant inhibition effect on the HER2-over-expression tumor (Morishita et al., 2010; Albarello et al., 2011; Schroeder et al., 2011; Liu et al., 2012; Somlo et al., 2012). As the time goes by, it is more and more concerned that the use of bispecific antibodies (BsAb) may be possible therapeutic agents for cancer treatment. Because of the important role in the process of antigen recognizing and activating, Anti-CD3 McAb is used as a member to construct double-functional antibody most frequently (Chatenoud, 2003). This article aims at evaluating the effect of HER-2×CD3 BsAb combined with peripheral blood lymph cells of normal human being on